Intuitive Surgical Inc. (ISRG) Pops 3.46% for February 10

Equities Staff  |

One of the S&P 500’s big winners for Wednesday February 10 was Intuitive Surgical Inc. (ISRG) as the company’s stock climbed 3.46% to $526.40 on volume of 191,176 shares.

The stock opened at $510.04 and saw an intraday low of $510.04 and an intraday high of $528.92. All told, the day saw a per-share gain of $17.58. The stock’s average daily volume of 371,950 and 37.38 million shares outstanding. Intuitive Surgical Inc. now has a 50-day SMA is $538.05 and 200-day SMA is $509.51, and it has a 52-week high of $580.00 and a 52-week low of $447.00.

Intuitive Surgical Inc designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories.

Based out of Sunnyvale, CA, Intuitive Surgical Inc. has 3,211 employees and, after today’s trading, reached a market cap of $19.68 billion. The stock’s P/E Ratio is 32.8. Its P/S ratio is 7.98, P/B ratio is 4.56, and P/FCF ratio is 27.5.

For a complete fundamental analysis analysis of Intuitive Surgical Inc., check out’s Stock Valuation Analysis report for ISRG. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.